Abstract
Lung transplantation is and established treatment option for end stage lung disease, although long-term clinical outcomes are halted by the onset of bronchiolitis obliterans syndrome and chronic lung allograft dysfunction (CLAD). To date diagnosis of CLAD relies on pulmonary function tests. No biologic marker has yet been clearly established to corroborate or anticipate the diagnosis. We sought to investigate role of broncho-alveolar surfactant phospholipids as a marker of CLAD by using a targeted lipidomic methodology.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
